Skip to main content
Erschienen in: Neurological Sciences 1/2012

01.05.2012 | SYMPOSIUM: PERIPHERAL NEUROMODULATION IN CHRONIC MIGRAINE

Peripheral neuromodulation in chronic migraine

verfasst von: F. Perini, A. De Boni

Erschienen in: Neurological Sciences | Sonderheft 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Patients with chronic migraines are often refractory to medical treatment. Therefore, they might need other strategies to modulate their pain, according to their level of disability. Neuromodulation can be achieved with several tools: meditation, biofeedback, physical therapy, drugs and electric neurostimulation (ENS). ENS can be applied to the central nervous system (brain and spinal cord), either invasively (cortical or deep brain) or non-invasively [cranial electrotherapy stimulation, transcranial direct current stimulation and transcranial magnetic stimulation]. Among chronic primary headaches, cluster headaches are most often treated either through deep brain stimulation or occipital nerve stimulation because there is a high level of disability related to this condition. ENS, employed through several modalities such as transcutaneous electrical nerve stimulation, interferential currents and pulsed radiofrequency, has been applied to the peripheral nervous system at several sites. We briefly review the indications for the use of peripheral ENS at the site of the occipital nerves for the treatment of chronic migraine.
Literatur
1.
Zurück zum Zitat D’Amico D, Grazzi L, Usai S, Raggi A, Leonardi M, Bussone G (2011) Disability in chronic daily headache: state of the art and future directions. Neurol Sci 32 Suppl 1:S71–6 D’Amico D, Grazzi L, Usai S, Raggi A, Leonardi M, Bussone G (2011) Disability in chronic daily headache: state of the art and future directions. Neurol Sci 32 Suppl 1:S71–6
2.
Zurück zum Zitat Lipton RB (2011) Chronic migraine, classification, differential diagnosis, and epidemiology. Headache 51(Suppl 2):77–83PubMedCrossRef Lipton RB (2011) Chronic migraine, classification, differential diagnosis, and epidemiology. Headache 51(Suppl 2):77–83PubMedCrossRef
3.
Zurück zum Zitat Manzoni GC, Bonavita V, Bussone G, Cortelli P, Narbone MC, Cevoli S, D’Amico D, De Simone R, Torelli P, On behalf of ANIRCEF (Associazione Neurologica Italiana Ricerca Cefalee) (2011) Chronic migraine classification: current knowledge and future perspectives. J Headache Pain 12:585–592PubMedCrossRef Manzoni GC, Bonavita V, Bussone G, Cortelli P, Narbone MC, Cevoli S, D’Amico D, De Simone R, Torelli P, On behalf of ANIRCEF (Associazione Neurologica Italiana Ricerca Cefalee) (2011) Chronic migraine classification: current knowledge and future perspectives. J Headache Pain 12:585–592PubMedCrossRef
4.
Zurück zum Zitat Goadsby PJ, Schoenen J, Ferrari M et al (2006) Towards a definition of refractory headache for use in clinical practice and trials. Cephalalgia 26:1168–1170PubMedCrossRef Goadsby PJ, Schoenen J, Ferrari M et al (2006) Towards a definition of refractory headache for use in clinical practice and trials. Cephalalgia 26:1168–1170PubMedCrossRef
5.
Zurück zum Zitat Schulman EA, Lake AE, Goadsby PJ et al (2008) Defining refractory migraine and refractory chronic migraine: proposed criteria from the refractory headache special interest section of the American Headache Society. Headache. 48:778–782PubMedCrossRef Schulman EA, Lake AE, Goadsby PJ et al (2008) Defining refractory migraine and refractory chronic migraine: proposed criteria from the refractory headache special interest section of the American Headache Society. Headache. 48:778–782PubMedCrossRef
6.
Zurück zum Zitat Schulman EA, Peterlin BL, Lake AE, Lipton RB, Hanlon A, Siegel S, Levin M, Goadsby PJ, Markley HG (2009) Defining refractory migraine: results of the RHSIS Survey of American Headache Society members. Headache 49:509–518PubMedCrossRef Schulman EA, Peterlin BL, Lake AE, Lipton RB, Hanlon A, Siegel S, Levin M, Goadsby PJ, Markley HG (2009) Defining refractory migraine: results of the RHSIS Survey of American Headache Society members. Headache 49:509–518PubMedCrossRef
7.
Zurück zum Zitat Irimia P, Palma JA, Fernandez-Torron R, Martinez-Vila E (2011) Refractory migraine in a headache clinic population. BMC Neurol 11:94 Irimia P, Palma JA, Fernandez-Torron R, Martinez-Vila E (2011) Refractory migraine in a headache clinic population. BMC Neurol 11:94
8.
Zurück zum Zitat Silberstein SD, Dodick DW, Pearlman S (2010) Defining the pharmacologically intractable headache for clinical trials and clinical practice. Headache 50:1499–1506PubMedCrossRef Silberstein SD, Dodick DW, Pearlman S (2010) Defining the pharmacologically intractable headache for clinical trials and clinical practice. Headache 50:1499–1506PubMedCrossRef
9.
Zurück zum Zitat Pattle RE, Weddell G (1948) Observations on electrical stimulation of pain fibres in an exposed human sensory nerve. J Neurophysiol 11(2):93–98PubMed Pattle RE, Weddell G (1948) Observations on electrical stimulation of pain fibres in an exposed human sensory nerve. J Neurophysiol 11(2):93–98PubMed
10.
Zurück zum Zitat Jenkins B, Tepper SJ (2011) Neurostimulation for primary headache disorders, part 1: pathophysiology and anatomy, history of neuromodulation in headache treatment, and review of peripheral neuromodulation in primary headaches. Headache 51(8):1254–1266 ReviewPubMedCrossRef Jenkins B, Tepper SJ (2011) Neurostimulation for primary headache disorders, part 1: pathophysiology and anatomy, history of neuromodulation in headache treatment, and review of peripheral neuromodulation in primary headaches. Headache 51(8):1254–1266 ReviewPubMedCrossRef
11.
Zurück zum Zitat Saper JR, Dodick DW, Silberstein SD, McCarville S, Sun M, Goadsby PJ, ONSTIM Investigators (2011) Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia 31(3):271–285PubMedCrossRef Saper JR, Dodick DW, Silberstein SD, McCarville S, Sun M, Goadsby PJ, ONSTIM Investigators (2011) Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia 31(3):271–285PubMedCrossRef
12.
Zurück zum Zitat Popeney C, Alo K (2003) Peripheral neurostimulation for the treatment of chronic, disabling transformed migraine. Headache 43:369–375PubMedCrossRef Popeney C, Alo K (2003) Peripheral neurostimulation for the treatment of chronic, disabling transformed migraine. Headache 43:369–375PubMedCrossRef
13.
Zurück zum Zitat Schwedt TJ, Dodick DW, Hentz J, Trentman TL, Zimmerman RS (2007) Occipital nerve stimulation for chronic headache—long-term safety and efficacy. Cephalalgia 27:153–157 Schwedt TJ, Dodick DW, Hentz J, Trentman TL, Zimmerman RS (2007) Occipital nerve stimulation for chronic headache—long-term safety and efficacy. Cephalalgia 27:153–157
14.
Zurück zum Zitat Trentman TL, Rosenfeld DM, Vargas BB, Schwedt TJ, Zimmerman RS, Dodick DW (2009) Greater occipital nerve stimulation via the Bion microstimulator: implantation technique and stimulation parameters. Clinical trial: NCT00205894. Pain Physician 12(3):621–628PubMed Trentman TL, Rosenfeld DM, Vargas BB, Schwedt TJ, Zimmerman RS, Dodick DW (2009) Greater occipital nerve stimulation via the Bion microstimulator: implantation technique and stimulation parameters. Clinical trial: NCT00205894. Pain Physician 12(3):621–628PubMed
15.
Zurück zum Zitat Silberstein S, Dodick D, Saper J, Huh B et al (2011) The safety and efficacy of peripheral nerve stimulation of the occipital nerve for the management of chronic migraine. Poster presented at: 15th Congress of the International Headache Society, Berlin, 23–26 June 2011 Silberstein S, Dodick D, Saper J, Huh B et al (2011) The safety and efficacy of peripheral nerve stimulation of the occipital nerve for the management of chronic migraine. Poster presented at: 15th Congress of the International Headache Society, Berlin, 23–26 June 2011
16.
Zurück zum Zitat D’Amico D, Leone M, Grazzi L, Bussone G (2008) When should “chronic migraine” patients be considered “refractory” to pharmacological to pharmacological prophylaxis? Neurol Sci 29:S55–S58PubMedCrossRef D’Amico D, Leone M, Grazzi L, Bussone G (2008) When should “chronic migraine” patients be considered “refractory” to pharmacological to pharmacological prophylaxis? Neurol Sci 29:S55–S58PubMedCrossRef
Metadaten
Titel
Peripheral neuromodulation in chronic migraine
verfasst von
F. Perini
A. De Boni
Publikationsdatum
01.05.2012
Verlag
Springer Milan
Erschienen in
Neurological Sciences / Ausgabe Sonderheft 1/2012
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-012-1039-4

Weitere Artikel der Sonderheft 1/2012

Neurological Sciences 1/2012 Zur Ausgabe

FICEF SYMPOSIUM: FROM FOOD TO MIGRAINE AND BACK

Migraine and metabolism

ANIRCEF SYMPOSIUM: MIGRAINE AND DEPRESSION

Migraine and depression: bidirectional co-morbidities?

MIGRAINE AS A RISK FACTOR

Migraine and movement disorders

THE FUTURE OF THERAPY IN HEADACHE

The therapeutic future in headache

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.